SRMC set to expand into U.S. market with belly fat treatment laser devices

[Courtesy of SRMC]

A South Korean medical device company is making strides in the U.S. market with its innovative laser equipment designed for fat reduction and wrinkle treatment.

On Sunday, SRMC announced that it has signed a supply agreement worth $20 million with Ambix, a U.S.-based biotech incubating and consulting firm. The deal involves the supply of SRMC’s anti-obesity device, SRA, and anti-aging device, SRS, to 1,500 hospitals across the U.S. through Ambix’s network.

Kim Yoo-in, CEO of SRMC, highlighted that these “triple gold” devices—so called for having successfully completed clinical trials, obtained patents, and received FDA approval in the U.S.—were developed with a total investment of 26 billion won.

“A set of three SRA devices and one SRS device, valued at 700 million won ($512,000), will be gradually deployed to 1,500 hospitals across the U.S. over the next four years,” Kim said.

As part of the agreement, SRMC plans to establish a local subsidiary in Delaware within the next three months. The company also aims to open a phototherapy equipment showroom and demo clinic in Beverly Hills, Los Angeles, to further expand its distribution network across the U.S.

The SRA device, designed to reduce belly fat, begins melting fat just 3 minutes and 30 seconds after being applied to the abdomen. The company assures that the treatment does not transfer heat to the skin, targeting only the fat beneath the surface.

CEO Kim expressed confidence in the U.S. market, saying, “By fully entering the U.S., we anticipate achieving annual sales of over 200 billion won within three years. While focusing on the U.S. market, which has a high obesity rate, we also plan to expand into the Middle East, including the UAE.”